J3374
J3374 – Inj, vancomycin (mylan) 10mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 17 NDCs crosswalked per 10 MG $0.097/unit ASP+6%
📋 J3374 summary
J3374 is a HCPCS Level II J-code used to bill vancomycin (mylan) 10mg, billed per 10 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J3374: Vancomycin Hcl(J3374), Vancomycin Hydrochloride
Code J3374
Billing unit 10 MG Payment limit $0.097/unit NDC-Crosswalk 17
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ3374
DescriptorInj, vancomycin (mylan) 10mg
Billing unit10 MG
Payment limit / unit$0.097
Est. ASP / unit$0.092 est.
Mapped NDCs17
Data periodQ3 2026
Last updated2026-08-20
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$0.097
Est. ASP / unit
$0.092 est.
Est. after 2% sequester
$0.095
HCPCS dosage
10 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J3374 = 10 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J3374 WITH EST. MEDICARE PAY
17 NDCs map to J3374. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($0.097/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 00143-9152-10 | Vancomycin Hydrochloride 1.25 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Hikma | 10 VIAL in 1 CARTON (0143-9152-10) / 1 IN... | 1.25 g/1 | 1,250 | $121.25 | — | ● Active | CMS + PDAC |
| 00143-9153-10 | Vancomycin Hydrochloride 1.5 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Hikma | 10 VIAL in 1 CARTON (0143-9153-10) / 1 IN... | 1.5 g/1 | 1,500 | $145.50 | — | ● Active | CMS + PDAC |
| 25021-0147-20 | Vancomycin Hydrochloride 750 mg/15mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Sagent | 10 VIAL in 1 CARTON (25021-147-20) / 15 m... | 750 mg/15mL | 750 | $72.75 | — | ● Active | CMS ASP |
| 25021-0148-30 | Vancomycin Hydrochloride 1.25 g/25mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Sagent | 10 VIAL in 1 CARTON (25021-148-30) / 25 m... | 1.25 g/25mL | 1,250 | $121.25 | — | ● Active | CMS + PDAC |
| 25021-0149-30 | Vancomycin Hydrochloride 1.5 g/30mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Sagent | 10 VIAL in 1 CARTON (25021-149-30) / 30 m... | 1.5 g/30mL | 1,500 | $145.50 | — | ● Active | CMS + PDAC |
| 39822-0460-02 | Vancomycin Hydrochloride 1.25 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | XGen | 10 VIAL in 1 CARTON (39822-0460-2) / 1 IN... | 1.25 g/1 | 1,250 | $121.25 | — | ● Active | CMS + PDAC |
| 39822-0470-02 | Vancomycin Hydrochloride 1.5 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | XGen | 10 VIAL in 1 CARTON (39822-0470-2) / 1 IN... | 1.5 g/1 | 1,500 | $145.50 | — | ● Active | CMS + PDAC |
| 55150-0471-10 | Vancomycin hydrochloride 1.25 g/25mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Eugia | 10 VIAL, SINGLE-DOSE in 1 CARTON (55150-47... | 1.25 g/25mL | 1,250 | $121.25 | — | ● Active | CMS + PDAC |
| 55150-0472-10 | Vancomycin hydrochloride 1.5 g/30mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Eugia | 10 VIAL, SINGLE-DOSE in 1 CARTON (55150-47... | 1.5 g/30mL | 1,500 | $145.50 | — | ● Active | CMS + PDAC |
| 67457-0705-75 | Vancomycin Hydrochloride 750 mg/15mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Mylan | 10 VIAL, SINGLE-DOSE in 1 CARTON (67457-70... | 750 mg/15mL | 750 | $72.75 | — | ● Active | CMS + PDAC |
| 67457-0823-99 | Vancomycin Hydrochloride 1.25 g/25mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Mylan | 10 VIAL, SINGLE-DOSE in 1 CARTON (67457-82... | 1.25 g/25mL | 1,250 | $121.25 | — | ● Active | CMS ASP |
| 67457-0824-99 | Vancomycin Hydrochloride 1.5 g/30mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Mylan | 10 VIAL, SINGLE-DOSE in 1 CARTON (67457-82... | 1.5 g/30mL | 1,500 | $145.50 | — | ● Active | CMS ASP |
| 68462-0477-74 | Vancomycin Hydrochloride 750 mg/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | GLENMARK | 10 VIAL, SINGLE-DOSE in 1 CARTON (68462-47... | 750 mg/1 | 750 | $72.75 | — | ● Active | CMS + PDAC |
| 68462-0478-84 | Vancomycin Hydrochloride 1.25 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | GLENMARK | 10 VIAL, SINGLE-DOSE in 1 CARTON (68462-47... | 1.25 g/1 | 1,250 | $121.25 | — | ● Active | CMS + PDAC |
| 68462-0479-84 | Vancomycin Hydrochloride 1.5 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | GLENMARK | 10 VIAL, SINGLE-DOSE in 1 CARTON (68462-47... | 1.5 g/1 | 1,500 | $145.50 | — | ● Active | CMS + PDAC |
| 72078-0065-99 | Vancomycin Hydrochloride 1.75 g/35mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Mylan | 10 VIAL, SINGLE-DOSE in 1 CARTON (72078-06... | 1.75 g/35mL | 1,750 | $169.75 | — | ● Active | CMS + PDAC |
| 72078-0066-99 | Vancomycin Hydrochloride 2 g/40mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Mylan | 10 VIAL, SINGLE-DOSE in 1 CARTON (72078-06... | 2 g/40mL | 2,000 | $194.00 | — | ● Active | CMS + PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$1.1K
Claims
38
Beneficiaries
32
Spend / beneficiary
$35.24
Spend / claim
$29.68
Trend by period
Where J3374 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #765 of 824
#760
CYTARABINE J9100
$1.2K
#761
POSACONAZOLE J1837
$1.2K
#762
BUMETANIDE J1939
$1.2K
#763
CEFOXITIN SODIUM* J0694
$1.2K
#764
GASTROGRAFIN* Q9963
$1.1K
#765
VANCOMYCIN HCL(J3374... J3374
$1.1K
#766
METHOCARBAMOL* J2800
$1.1K
#767
TYZAVAN* J3375
$1.1K
#768
PENICILLIN G POTASSI... J2540
$1.1K
#769
STREPTOMYCIN SULFATE J3000
$1.1K
#770
AMPHOTERICIN B J0285
$1.1K
Total claims — #723 of 824
#718
PHYTONADIONE* J3430
39
#719
MITOXANTRONE HCL J9293
39
#720
RUCONEST J0596
38
#721
CHLOROTHIAZIDE SODIU... J1205
38
#722
FLUCONAZOLE-NACL J1450
38
#723
VANCOMYCIN HCL(J3374... J3374
38
#724
PERSERIS J2798
37
#725
XYNTHA SOLOFUSE* J7185
37
#726
PEMETREXED(J9314) J9314
37
#727
TYZAVAN* J3375
35
#728
HEPZATO J9248
35
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $1.1K | 32 | 38 | $35.24 | $29.68 |
| 2025 (Q1-Q4) | $3.5K | 49 | 94 | $70.48 | $36.74 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$889.10
Medicare paid
$633.02
Submitted services
29,681
Denial rate
74.5%
Allowed / service
$0.12
Submitted charges
$31.1K
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J3374 is utilized
⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.
📊 What bills under J3374
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Not available in current dataset
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
17 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J3374 billing FAQ
What is HCPCS code J3374?
J3374 is a HCPCS Level II J-code used to bill Inj, vancomycin (mylan) 10mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J3374?
One unit of J3374 represents 10 MG. Report the number of units equal to the dose administered divided by 10 MG.
How many units of J3374 should I bill?
Divide the dose administered by the code's unit size (10 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J3374?
The Medicare Part B payment limit is $0.097 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $0.095 per unit. Payment limits are revised quarterly.
Which NDCs bill under J3374?
17 NDCs currently map to J3374 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J3374 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.